Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 781 to 790 of 1090 total matches.
Mirikizumab (Omvoh) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Mar 18, 2024 (Issue 1698)
of mirikizumab
in breast milk or its effects on the breastfed infant or
milk production.
DRUG INTERACTIONS ...
The FDA has approved the interleukin (IL)-23
antagonist mirikizumab-mrkz (Omvoh – Lilly) for
treatment of moderately to severely active ulcerative
colitis (UC) in adults. Mirikizumab is the first selective
IL-23 antagonist to be approved for this indication.
Ustekinumab (Stelara), an IL-12/23 antagonist, was
approved for treatment of UC in 2019. The IL-23
antagonist risankizumab (Skyrizi) is approved for
treatment of Crohn's disease.
Med Lett Drugs Ther. 2024 Mar 18;66(1698):46-7 doi:10.58347/tml.2024.1698c | Show Introduction Hide Introduction
Glyxambi - A New Combination for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Apr 27, 2015 (Issue 1467)
in women) for use during pregnancy.
DRUG INTERACTIONS — Hypoglycemia can occur
if Glyxambi is used ...
The FDA has approved Glyxambi (Boehringer
Ingelheim/Lilly), a fixed-dose combination of empagliflozin
(Jardiance) and linagliptin (Tradjenta), for oral
treatment of type 2 diabetes in adults. It is the first
combination of a sodium-glucose co-transporter 2
(SGLT2) inhibitor and a dipeptidyl peptidase-4 (DPP-4) inhibitor to be approved in the US.
Wellbutrin Versus Generic Bupropion
The Medical Letter on Drugs and Therapeutics • Jul 14, 2008 (Issue 1290)
Letter
®
On Drugs and Therapeutics
Volume 50 (Issue 1290)
July 14, 2008
www.medicalletter.org ...
Bupropion (Wellbutrin - GlaxoSmithKline, and others) is a norepinephrine and dopamine reuptake inhibitor that has been a useful antidepressant because, unlike some other antidepressants, it does not cause sexual dysfunction, weight gain or sedation. Some patients who were switched from Wellbutrin to a generic alternative have reported worsening side effects and relapse of previously controlled depressive symptoms.1 Most of the complaints have come from patients switched from Wellbutrin XL 300 mg to the generic 300-mg formulation of extended-release bupropion marketed by Teva (Budeprion XL).2...
Empagliflozin/Metformin (Synjardy) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Dec 21, 2015 (Issue 1484)
pregnancy.
DRUG INTERACTIONS — Hypoglycemia can occur
if Synjardy is taken with insulin or a sulfonylurea ...
The FDA has approved Synjardy (Boehringer Ingelheim/Lilly), a fixed-dose combination of the sodium-glucose
co-transporter 2 (SGLT2) inhibitor empagliflozin
(Jardiance) and metformin (Glucophage, and others),
for treatment of patients with type 2 diabetes not
adequately controlled on either of these drugs alone
or already being treated with both empagliflozin and
metformin. It is the third SGLT2 inhibitor/metformin
combination to be approved in the US.
Saxagliptin/Metformin (Kombiglyze XR) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Mar 21, 2011 (Issue 1360)
(no evidence of
risk, no adequate studies in pregnant women) for use
in pregnancy.
DRUG INTERACTIONS ...
Metformin (Glucophage, and others) is generally preferred as the first-line agent for treatment of type 2 diabetes, but most patients subsequently require treatment with more than one drug. Many combination products have been marketed; the latest of these combines saxagliptin with extended-release (ER) metformin as
Kombiglyze XR.
Two Amlodipine/ARB Combinations for Hypertension
The Medical Letter on Drugs and Therapeutics • Dec 17, 2007 (Issue 1276)
Letter
®
On Drugs and Therapeutics
Two Amlodipine/ARB Combinations
for Hypertension
Volume 49 ...
The FDA has approved Exforge (Novartis) and Azor (Daiichi Sankyo), the first combinations of a calcium channel blocker (CCB) with an angiotensin receptor blocker (ARB) for treatment of hypertension. Amlodipine is the CCB in both products. The ARBs are valsartan in Exforge and olmesartan in Azor. All 3 of these drugs are available in fixed-dose combinations with other antihypertensive drugs.
Cobimetinib (Cotellic) for Metastatic Melanoma
The Medical Letter on Drugs and Therapeutics • Mar 28, 2016 (Issue 1491)
in pregnant rats at doses 0.9-1.4 times the
recommended human dose.
DRUG INTERACTIONS — Cobimetinib ...
The FDA has approved the mitogen-activated
extracellular signal-regulated kinase (MEK) inhibitor
cobimetinib (Cotellic – Genentech) for use in combination
with the BRAF kinase inhibitor vemurafenib
(Zelboraf) for treatment of unresectable or metastatic
melanoma with a BRAF V600E or V600K mutation.
Long-Acting Injectable Aripiprazole (Abilify Maintena) for Schizophrenia
The Medical Letter on Drugs and Therapeutics • Apr 29, 2013 (Issue 1415)
during pregnancy.
DRUG INTERACTIONS — Administration of aripiprazole
with a CYP3A4 inducer ...
An extended-release injectable formulation of the
second-generation antipsychotic aripiprazole
(Abilify) has been approved by the FDA (Abilify
Maintena – Otsuka/Lundbeck) for once-monthly treatment of schizophrenia. It is the fourth second-generation
antipsychotic to become available in a
long-acting parenteral formulation. Long-acting parenteral
antipsychotics, given at intervals of 2-4
weeks, are generally used for patients with a history
of relapse due to poor adherence to oral maintenance
therapy.
Naldemedine (Symproic) for Opioid-Induced Constipation
The Medical Letter on Drugs and Therapeutics • Dec 04, 2017 (Issue 1535)
of the immaturity of the fetal blood-brain barrier.
DRUG INTERACTIONS – Naldemedine is metabolized
primarily ...
The FDA has approved the opioid receptor antagonist
naldemedine (Symproic – Shionogi) for treatment
of opioid-induced constipation (OIC) in adults with
chronic noncancer pain. Naldemedine is the third oral
peripherally-acting mu-opioid receptor antagonist
(PAMORA) to be approved for this indication; naloxegol
(Movantik) and methylnaltrexone (Relistor) were
approved earlier.
Extended-Release Amantadine (Gocovri) for Dyskinesia in Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Dec 04, 2017 (Issue 1535)
of parkinsonian symptoms,
confusion, neuroleptic malignant syndrome, and
acute delirium.
DRUG INTERACTIONS ...
The FDA has approved an extended-release (ER)
capsule formulation of amantadine (Gocovri –
Adamas) for once-daily treatment of levodopa-induced
dyskinesia in patients with Parkinson's
disease (PD). It is the first product to be approved
in the US for this indication. Immediate-release (IR)
amantadine has been used off-label for years to
manage levodopa-induced dyskinesia.